| Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome) |
Gusarova, V.D., Smolov, M.A., Lyagoskin, I.V. et al. |
2023 |
BioDrugs |
THP-0178
|
| iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II |
Hong, J., Cheng, Y., Yang, S.,et al. |
2022 |
Experimental Cell Research |
THP-0178
|
| Contributions of thrombin targets to tissue factor‐dependent metastasis in hyperthrombotic mice |
Yokota, N., Zarpellon, A., Chakrabarty, S.,et al. |
2014 |
Journal of Thrombosis and Haemostasis |
THP-0212
|
| Analysis of Botulinum Toxin A and Interacting Proteins in Skeletal Muscle Cells: An Investigation into the Mechanisms behind Botulinum Toxin A as a Treatment for Chronic Exertional Compartment Syndrome |
Kee, Lauren |
2022 |
Honors Program Projects |
THP-0027
|
| Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins |
Nguyen, N. H., Glassman, F. Y., Dingman, R. K.,et al. |
2021 |
Scientific Reports |
THP-0146
|
| Antibody-based strategies for the detection of Luspatercept (ACE-536) in human serum |
Reichel, C., Gmeiner, G., & Thevis, M. |
2017 |
Drug Testing and Analysis |
THP-0319
|
| Detection of Sotatercept (ACE-011) in human serum by SAR-PAGE and western single blotting |
Reichel, C., Farmer, L., Gmeiner, G.,et al. |
2017 |
Drug Testing and Analysis |
THP-0319
|
| Testing for the erythropoiesis-stimulating agent Sotatercept/ACE-011 (ActRIIA-Fc) in serum by means of Western blotting and LC-HRMS |
Walpurgis, K., Thomas, A., Vogel, M.,et al. |
2016 |
Drug Testing and Analysis |
THP-0319
|
| Generation of a Universal Human Complement Source by Large-Scale Depletion of IgG and IgM from Pooled Human Plasma |
Frances Alexander, Emily Brunt, Holly Humphries,et al. |
2021 |
Bacterial Vaccines |
THP-0082
|
